Health-related quality of life in patients with newly diagnosed multiple myeloma ineligible for stem cell transplantation: results from the randomized phase III ALCYONE trial - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34078314/
doi: 10.1186/s12885-021-08325-2. 1 Department of Haematology and Oncology, Würzburg University Medical Center, Oberdürrbacher Straße 6, 97080, Würzburg, Germany. [email protected]. 2 University Hospital of Salamanca-Instituto de Investigación Biomédica de Salamanca, Salamanca,...
Propensity-score matched analysis of the efficacy of maintenance/continuous therapy in newly diagnosed patients with multiple myeloma: a multicenter retrospective collaborative study of the Japanese Society of Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34080068/
doi: 10.1007/s00432-021-03668-6. Online ahead of print. 1 Department of Hematology, Tokushima Prefectural Central Hospital, 1-10-3 Kuramoto, Tokushima, 770-8539, Japan. [email protected]. 2 Department of Hematology, Gunma University Graduate School of Medicine,...
M3258 is a selective inhibitor of the immunoproteasome subunit LMP7 (β5i) delivering efficacy in multiple myeloma models - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34045234/
2021 May 27;molcanther.MCT-21-0005-A.2021. doi: 10.1158/1535-7163.MCT-21-0005. Online ahead of print. 1 Translational Innovation Platform Oncology & Immuno-Oncology, Merck KGaA, Darmstadt, Germany [email protected]. 2 Merck KGaA. 3 Merck KGaA, Darmstadt, Germany. 4...
Validation of an Instrument for Measuring Adherence to Treatment With Immunomodulators in Patients With Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34045961/
doi: 10.3389/fphar.2021.651523. 1 Hospital das Clínicas, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 2 Faculdade de Farmácia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil. 3 Fundação Ezequiel Dias,...
Ocular Toxicity of Belantamab Mafodotin, an Oncological Perspective of Management in Relapsed and Refractory Multiple Myeloma - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/34046363/
Belantamab mafodotin (belamaf), an antibody-drug conjugate approved for the treatment of relapsed and refractory multiple myeloma (RRMM), is an anti B-cell maturation antigen (BCMA) agent. DREAMM-1, a first in-human trial...